Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta

Journal of Bone and Mineral Metabolism

Volumn 26, Issue 4, 2008, Pages 394-399

  Hasegawa, Kosei ^a   Kataoka, Kyoko ^a   Inoue, Masaru ^a   Seino, Yoshiki ^b   Morishima, Tsuneo ^a   Tanaka, Hiroyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Hydroxyproline; NTx CTx; Osteogenesis imperfecta; Pyridinoline cross link

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; HYDROXYPROLINE; PYRIDINOLINE;

ARTICLE; BONE FRAGILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OSTEOGENESIS IMPERFECTA; PEDIATRICS; PRIORITY JOURNAL; URINALYSIS;

AMINO ACIDS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; CROSS-LINKING REAGENTS; FEMALE; HUMANS; HYDROXYPROLINE; MALE; OSTEOGENESIS IMPERFECTA; PEPTIDES;

EID: 46749150972     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-007-0827-z     Document Type: Article

References (27)

1. Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116
2. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ (2000) Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 15:1650-1658
3. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30-38
4. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone (NY) 31:12-18
5. Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, et al (1990) Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 46:293-307
6. Kok DJ, Uiterwaal CS, Van Dongen AJ, Kramer PP, Pruijs HE, Engelbert RH, Verbout AJ, Schweitzer DH, Sakkers RJ (2003) The interaction between Sillence type and BMD in osteogenesis imperfecta. Calcif Tissue Int 73:441-445
7. Brenner RE, Schiller B, Vetter U, Ittner J, Teller WM (1993) Serum concentrations of procollagen I C-terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with nonlethal osteogenesis imperfecta. Acta Paediatr 82:764-767
8. Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S (2004) Bone turnover markers in patients with osteogenesis imperfecta. Bone (NY) 34:1013-1016
9. Lund AM, Hansen M, Kollerup G, Juul A, Teisner B, Skovby F (1998) Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr 87:1131-1137
10. Korkko J, Ala-Kokko L, De Paepe A, Nuytinck L, Earley J, Prockop DJ (1998) Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am J Hum Genet 62: 98-110
11. Ward LM, Lalic L, Roughley PJ, Glorieux FH (2001) Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV. Hum Mutat 17:434
12. Starman BJ, Eyre D, Charbonneau H, Harrylock M, Weis MA, Weiss L, Graham JM Jr, Byers PH (1989) Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1 (I) chains of type I collagen determines the clinical phenotype. J Clin Invest 84:1206-1214
13. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M (2005) Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97-104
14. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, Abbiati G, Chiumello G (1998) Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 63:369-374
15. Cloos PA, Fledelius C (2000) Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J 345(pt 3):473-480
16. Wharton BA, Gough G, Williams A, Kitts S, Pennock CA (1972) Urinary total hydroxyproline: creatinine ratio. Range of normal, and clinical application in British children. Arch Dis Child 47: 74-79
17. Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y (1995) Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metab 80:1922-1928
18. Bollen AM, Eyre DR (1994) Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone (NY) 15:31-34
19. Taguchi Y, Gorai I, Zhang MG, Chaki O, Nakayama M, Minaguchi H (1998) Differences in bone resorption after menopause in Japanese women with normal or low bone mineral density: quantitation of urinary cross-linked N-telopeptides. Calcif Tissue Int 62:395-399
20. Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785
21. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked Ntelopeptides in urine. J Bone Miner Res 7:1251-1258
22. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025
23. Fledelius C, Johnsen AH, Cloos PA, Bonde M, Qvist P (1997) Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha 1) region. J Biol Chem 272:9755-9763
24. Gineyts E, Cloos PA, Borel O, Grimaud L, Delmas PD, Garnero P (2000) Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem J 345(pt 3):481-485
25. Ha-Vinh R, Alanay Y, Bank RA, Campos-Xavier AB, Zankl A, Superti-Furga A, Bonafe L (2004) Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2. Am J Med Genet A 131:115-120
26. Bank RA, Tekoppele JM, Janus GJ, Wassen MH, Pruijs HE, Van der Sluijs HA, Sakkers RJ (2000) Pyridinium cross-links in bone of patients with osteogenesis imperfecta: evidence of a normal intrafibrillar collagen packing. J Bone Miner Res 15:1330-1336
27. Dominguez LJ, Barbagallo M, Moro L (2005) Collagen overglycosylation: a biochemical feature that may contribute to bone quality. Biochem Biophys Res Commun 330:1-4